Coeptis Therapeutics (COEP) director adds shares via option exercise, grant

Rhea-AI Filing Summary

Coeptis Therapeutics Holdings, Inc. director Gene Salkind reported acquiring additional common stock on February 11, 2026. He exercised stock options for 5,700 shares at $10.56 per share and also received a grant of 3,250 restricted shares through an option exchange program.

After these transactions, Salkind beneficially owns 13,161 shares of Coeptis common stock directly. This total includes 4,211 shares held as JTWROS with Catherine Salkind, meaning they share beneficial ownership of that portion.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Salkind Gene

Role Director

Type	Security	Shares	Price	Value
Exercise	Common stock	5,700	$10.56	$60K
Grant/Award	Common Stock	3,250	$0.00	--

Holdings After Transaction: Common stock — 13,161 shares (Direct); Common Stock — 13,161 shares (Direct)

Footnotes (1)

1. Represents the exercise price of shares purchased upon exercise of stock options. Represents a grant of restricted stock issued in connection with an option exchange program where the Reporting Person surrendered underwater options in exchange for a grant of restricted stock. Includes 4,211 shares of common stock that are held as JTWROS with Catherine Salkind.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Salkind Gene

(Last) (First) (Middle)

105 BRADFORD ROAD

SUITE 420

(Street)

WEXFORD PA 15090

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Coeptis Therapeutics Holdings, Inc. [ COEP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	02/11/2026		M		5,700	A	$10.56(1)	13,161	D(3)
Common Stock	02/11/2026		A		3,250	A	$0(2)	13,161	D(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the exercise price of shares purchased upon exercise of stock options.

2. Represents a grant of restricted stock issued in connection with an option exchange program where the Reporting Person surrendered underwater options in exchange for a grant of restricted stock.

3. Includes 4,211 shares of common stock that are held as JTWROS with Catherine Salkind.

	/s/ Gene Salkind	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Gene Salkind report in this Form 4 for COEP?

Gene Salkind reported acquiring Coeptis Therapeutics common stock through an option exercise and a restricted stock grant. The filing shows both the number of shares involved and his total beneficial ownership after these transactions.

How many Coeptis (COEP) shares did Salkind acquire by option exercise?

Salkind acquired 5,700 Coeptis common shares by exercising stock options at an exercise price of $10.56 per share. This transaction is coded “M” for an exercise or conversion of a derivative security in the Form 4 filing.

What restricted stock grant did Salkind receive from Coeptis (COEP)?

Salkind received a grant of 3,250 shares of restricted Coeptis common stock at a price of $0. The grant occurred in an option exchange program after he surrendered underwater options in return for restricted stock, as described in the footnotes.

How many Coeptis (COEP) shares does Salkind own after these transactions?

After the reported transactions, Salkind beneficially owns 13,161 shares of Coeptis common stock. This total reflects both the option exercise and the restricted stock grant reported as of February 11, 2026 in the Form 4 filing.

What does the Coeptis (COEP) Form 4 say about JTWROS shares?

The filing notes that Salkind’s beneficial ownership total includes 4,211 Coeptis common shares held as JTWROS with Catherine Salkind. This means those 4,211 shares are jointly held with her as reflected in the ownership footnote.